Finanzen von SeaStar Medical Holding Corp (ICU)ICUSeaStar Medical Holding Corp

Evaluating the bottom line, SeaStar Medical Holding Corp maintains a gross margin of 91.22%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -616.42%, while the net margin is -606.50%. These profitability ratios, combined with a Return on Equity (ROE) of -356.87%, provide a clear picture of how effectively ICU converts its operational activities into shareholder value.

In the context of the broader market, ICU competes directly with industry leaders such as IRIX and HSCS. With a market capitalization of $13.62M, it holds a significant position in the sector. When comparing efficiency, ICU's gross margin of 91.22% stands against IRIX's 34.19% and HSCS's 59.06%. Such benchmarking helps identify whether SeaStar Medical Holding Corp is trading at a premium or discount relative to its financial performance.

SeaStar Medical has shown a gross margin of 90.71% in Q1 2026, indicating strong profitability relative to sales, but it continues to report significant net income losses, with a loss of $3.73 million in Q2 2026.